Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Mar 7, 2021 6:41 AM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Mirum Pharmaceuticals to Present at Upcoming Investor Conferences

February 22, 2021

FOSTER CITY, Calif. --(BUSINESS WIRE)--Feb. 22, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the company will participate in the following upcoming virtual investor conferences: SVB Leerink 10 th Annual Global Healthcare Conference Friday, February 26, 2021 at 3:40 p.m.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 10, 2021

FOSTER CITY, Calif. --(BUSINESS WIRE)--Feb. 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 21,500 shares of common stock

Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome

February 1, 2021

- Maralixibat U.S. launch expected in second half of 2021, if approved FOSTER CITY, Calif. --(BUSINESS WIRE)--Feb. 1, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced it has completed submission of its rolling New Drug Application (NDA) to the U.S.

Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign

January 24, 2021

- The national campaign seeks to emphasize the unbearable burden ALGS has on patients and their families. - Mirum underscores its commitment to continued understanding of the rare liver disease through research and support of ALGS community. FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan.

Events

Oppenheimer 31st Annual Healthcare Conference

Mar 17, 2021 at 3:50 PM EDT

Add to Outlook

Add to Google Calendar

H.C. Wainwright Global Life Sciences Conference

Mar 9, 2021

Add to Outlook

Add to Google Calendar

Raymond James Virtual Institutional Investors Conference

Mar 3, 2021 at 3:00 PM EST

Click here for webcast

Investor Relations

Investor Relations

Corporate Profile

Header Menu